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Background: There is increasing evidence that botulinum neurotoxin A may affect sensory 
nociceptor fibers, but the expression of its receptors in clinical pain states, and its effects in 
human sensory neurons, are largely unknown.
Methods: We studied synaptic vesicle protein subtype SV2A, a receptor for botulinum 
 neurotoxin A, by immunostaining in a range of clinical tissues, including human dorsal root 
 ganglion sensory neurons, peripheral nerves, the urinary bladder, and the colon. We also  determined 
the effects of botulinum neurotoxins A and E on localization of the capsaicin receptor, TRPV1, 
and functional sensitivity to capsaicin stimuli in cultured human dorsal root ganglion neurons.
Results: Image analysis showed that SV2A immunoreactive nerve fibers were increased in 
injured nerves proximal to the injury (P = 0.002), and in painful neuromas (P = 0.0027); the ratio 
of percentage area SV2A to neurofilaments (a structural marker) was increased proximal to injury 
(P = 0.0022) and in neuromas (P = 0.0001), indicating increased SV2A levels in injured nerve 
fibers. In the urinary bladder, SV2A nerve fibers were found in detrusor muscle and associated 
with blood vessels, with a significant increase in idiopathic detrusor overactivity (P = 0.002) 
and painful bladder syndrome (P = 0.0087). Colon biopsies showed numerous SV2A-positive 
nerve fibers, which were increased in quiescent inflammatory bowel disease with abdominal 
pain (P = 0.023), but not in inflammatory bowel disease without abdominal pain (P = 0.77) 
or in irritable bowel syndrome (P = 0.13). In vitro studies of botulinum neurotoxin A-treated 
and botulinum neurotoxin E-treated cultured human sensory neurons showed accumulation of 
cytoplasmic vesicles, neurite loss, and reduced immunofluorescence for the heat and capsaicin 
receptor, TRPV1. Functional effects included dose-related inhibition of capsaicin responses on 
calcium imaging after acute treatment with botulinum neurotoxins A and E.
Conclusion: Differential levels of SV2A protein expression in clinical disorders may identify 
potential new targets for botulinum neurotoxin therapy. In vitro studies indicate that treatment 
with botulinum neurotoxins A and E may affect receptor expression and nociceptor function 
in sensory neurons.
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Introduction
SV2A, a synaptic vesicle protein isoform, has been shown to be the high-affinity 
 botulinum neurotoxin A receptor that mediates binding and internalization of the 
 neurotoxin into peripheral neurons.1 Synaptic vesicle protein (SV2) is  approximately 
90 kDa glycoprotein component of all mammalian synaptic vesicles.2–4 In  addition to 
the SV2A subtype protein, neuronal binding of botulinum neurotoxin also involves a 
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 ganglioside coreceptor within the presynaptic membrane.5 
Cleavage of soluble NSF attachment  protein receptor 
(SNARE) proteins within the presynaptic  terminal by 
botulinum neurotoxin leads to prevention of the  formation 
of a  productive docking complex necessary for  transmitter 
release, and consequent loss of function, eg, at the 
 neuromuscular junction.  Synaptosomal-associated protein 
(SNAP-25) is the SNARE protein that is specifically cleaved 
by type A toxin.1,6
Levels of SV2A, one of the SV2 isoforms to which 
botulinum neurotoxin A binds, are largely undetermined 
in clinical disorders, particularly in patients with pain and 
visceral dysfunction. Because botulinum neurotoxin A treat-
ment is being considered increasingly in such conditions, 
we have studied SV2A protein in tissues from patients with 
nerve injury and pelvic visceral disorders, and the effects of 
botulinum neurotoxin in cultured human sensory neurons.
Recent studies in rodents have indicated the potential of 
botulinum neurotoxin A to affect sensory mechanisms via 
inhibition of neurotransmitters from sensory afferent nerves.7 
A novel chimera (EA) botulinum neurotoxin A and E sero-
type inhibited calcitonin gene-related peptide release from 
trigeminal ganglionic neurons and eliminated the excitatory 
effects of this peptide in brain stem sensory neurons evoked 
by capsaicin, which activates the transient receptor potential 
vanilloid receptor type 1 (TRPV1).8
TRPV1 is the neuronal receptor for capsaicin (the hot 
ingredient of chilli peppers), low pH, heat, and inflamma-
tory mediators, such as bradykinin, arachidonic acid and its 
metabolites, and mediates the perception of pain via calcium 
influx and membrane depolarization.9 TRPV1 expression is 
increased in conditions of chronic pain,10,11 and the receptor 
demonstrates sensitization in the presence of neurotrophic 
factors in models of pain.12,13 Capsaicin has been extensively 
used as a tool for studies of TRPV1 function.
Botulinum neurotoxin is potentially a promising treat-
ment for chronic somatic and visceral pain,14 which by 
definition lasts for more than 3 months. These conditions 
include pelvic neurogenic hypersensitivity disorders, such as 
painful bladder syndrome14,15 and irritable bowel syndrome, 
in which pain is attributed at least in part to dysfunction 
or sensitization of the peripheral nervous system. The 
 mechanisms of chronic visceral pain are complex, and have 
been reviewed.16 Neural plasticity may lead to chronic pain 
in these conditions, including upregulation of TRPV1 in 
peripheral nerve terminals.17–20 Botulinum neurotoxin may 
prevent membrane surface expression of TRPV1, thereby 
reducing hypersensitivity.21,22
We examined the distribution of SV2A in a range of 
control and clinical disease tissues, some involving pain, 
in order to identify patient groups that may be potential 
and preferential targets for botulinum neurotoxin therapy, 
and also determined the effects of botulinum neurotoxins 
A and E on sensory neuron morphology, TRPV1 expres-
sion, and responses to capsaicin in cultured human dorsal 
root ganglion neurons.
Materials and methods
Tissue collection
A range of tissues were used in this study, for which fully 
informed consent was obtained with approval of the relevant 
research ethics committees. Specimens were snapfrozen in 
liquid nitrogen and stored at −70°C until use or immersed 
in Zamboni’s fixative (2% w/v formalin, 0.1 M phosphate, 
and 15% v/v saturated picric acid) for 2 hours and stored in 
phosphate-buffered saline.
Specimens of nerve proximal to the site of injury (n = 6, 
mean age [± standard error of the mean] 29.0 ± 4.8 years, 
two females, range of injury delay 1.5 days to 12 months), 
neuroma (n = 21, mean age 23.3 ± 2.8 years, four females, 
range of injury delay 1.5–13 months), and dorsal root gan-
glia (n = 8, mean age 31.5 ± 6.0 years, one female, range of 
injury delay 3 days to 5 months) were obtained from patients 
undergoing surgery for painful neuroma relocation, brachial 
plexus repair, or peripheral nerve repair. Uninjured nerves 
(n = 7, mean age 41.6 ± 10.6 years, two females) used as 
nerve repair grafts during surgery served as controls.
Urinary bladder tissue specimens were obtained from 
control subjects under investigation for asymptomatic micro-
scopic hematuria (control group, n = 8, mean age 51.1 [range 
31–79] years, five females), idiopathic detrusor overactivity 
(n = 6, mean age 52.1 [range 32–73] years, four females) 
and painful bladder syndrome (n = 8, mean age 49.6 [range 
29–71] years, six females) who met the National Institute of 
Diabetes and Digestive and Kidney Diseases research criteria 
for interstitial cystitis, as described by our group previously.23 
The patients with idiopathic detrusor overactivity presented 
with overactive bladder symptoms, ie, urgency, with or 
without urge incontinence, frequency, and nocturia, and 
showed involuntary detrusor contractions during the filling 
phase of urodynamics.
Colonoscopic rectosigmoid biopsies were collected from 
patients with either quiescent or asymptomatic quiescent 
inflammatory bowel disease (n = 25, 14 ulcerative colitis, 
11 Crohn’s disease, eight females, mean age 54.3 ± 3.0 [range 
30–80] years), as previously described.19 Irritable bowel 
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syndrome (n = 14, mean age 46.8 ± 8.0 [range 25–77] 
years) was diagnosed according to Rome II criteria, and the 
subjects were further classified according to Rome II crite-
ria, as described eleswhere.10,19 Controls (n = 13, mean age 
60.8 ± 4.1 [range 39–85] years, 10 females) were selected 
from patients who were undergoing colonoscopy for other 
indications (such as polyp and cancer surveillance) and had 
a normal colon. For inflammatory bowel disease, abdominal 
pain scores were recorded using a validated questionnaire 
and samples were subdivided into those with (n = 10, mean 
age 56 [range 40–66] years) or without (n = 15, mean age 
57 [range 47–63] years) pain.
Immunohistochemistry
Frozen tissue sections (15 µm thickness) were postfixed in 
4% w/v paraformaldehyde in 0.15 M phosphate-buffered 
saline for 30 minutes. Endogenous peroxidase was blocked 
by incubation in industrial methylated spirits containing 
0.3% w/v hydrogen peroxide for 30 minutes. After rehy-
dration with phosphate-buffered saline, the sections were 
incubated overnight with a primary antibody using a range 
of dilutions. Rabbit SV2A polyclonal antibody was obtained 
from Sigma-Aldrich (Dorset, UK) and used at the optimal 
dilution 1:750. The SV2A antibody used in this study has 
not been reported before, although immunohistochemistry 
expression profiles provided by the manufacturer indicate 
strong staining of neuropils in the central nervous system. 
Localization of SV2A immunoreactivity was similar in both 
prefixed and postfixed tissues. SV2A antibodies were evalu-
ated by titration on tissue sections of dorsal root ganglia and 
injured nerve tissue. Immunoreaction with sensory neurons 
and nerve fibers diminished with increasing antibody dilu-
tion, with very weak residual immunoreactivity at 1:1000. 
A cocktail of monoclonal antibodies to the phosphorylated 
and nonphosphorylated neurofilaments of size 200 kDa 
(Clone N52, Sigma-Aldrich, Poole, UK) and the 57 kDa 
type III filament, peripherin (Novocastra Laboratories, 
Newcastle, UK) were used at final titers of 1:20,000 and 
1:500 respectively, and acted as structural neuronal markers. 
Sites of primary antibody attachment were revealed using 
nickel-enhanced avidin-biotin peroxidase (ABC, Vector 
Laboratories,  Peterborough, UK).
Image analysis
SV2A immunoreactivity was assessed quantitatively by 
computerized image analysis whereby images were captured 
using an Olympus DP70 camera mounted onto an Olympus 
BX50 microscope and analyzed using Olympus AnalySIS® 
(version 5.0) software. Positive immunostaining was high-
lighted by setting the gray-level detection limits to threshold, 
and the area of highlighted immunoreactivity was obtained 
as percent area of the field scanned. Five random fields per 
tissue section were scanned at the same magnification (40×). 
Results were expressed as percent area. The Mann–Whitney 
test was used for statistical analysis (P values , 0.05 were 
considered statistically significant).
Neuronal culture
Avulsed human cervical ganglia (n = 5) were obtained by 
ganglionectomy at the Royal National Orthopaedic  Hospital, 
Stanmore, as a necessary part of the surgical repair procedure, 
with informed patient consent and approval of the research 
ethics committee. The ganglia were minced, enzyme-
digested in 0.5% dispase (8 U/mg) and 0.2%  collagenase 
(168 U/mg), and penicillin + streptomycin (100 µg/mL each) 
in Ham’s F12 nutrient medium for 3 hours, and mechani-
cally dissociated to obtain a cell suspension. Cells were 
plated onto Mattek dishes coated with collagen 20 µg/mL 
and laminin 20 µg/mL for 20 minutes. Ham’s F12 nutrient 
medium containing 10% heat-inactivated fetal calf serum 
and recombinant human neurotrophic factors, ie, rhNGF 
100 ng/mL and rhGDNF 50 ng/mL, were added, and the 
cells were incubated in a humid environment with 8% CO
2
. 
The medium was changed every 3–4 days. Neuronal enrich-
ment by removal of non-neuronal cells was not carried out, 
so as to maximize the neuronal yield. Studies were conducted 
48 hours after plating.
TRPV1 immunostaining
Established neuron cultures were treated with or without 
botulinum neurotoxin A 0.1 nM and 1 nM and botulinum 
neurotoxin E 0.1 nM for one hour, fixed in 4% paraformalde-
hyde for 15 minutes, and double-immunostained for TRPV1 
(rabbit polyclonal anti-TRPV1 1:1000), and Gap43 (growth-
associated protein mouse monoclonal 1:200), visualized with 
goat antirabbit Alexa 546 and goat antimouse Alexa 488 
(secondary antibodies, 1:200 Molecular Probes®), and mounted 
in glycerol containing DABCO antifade agent, as previously 
described.24 TIFF images were acquired using Smartcapture 
3.0 software (Digital Scientific, Cambridge, UK), on an upright 
Olympus microscope, at a fixed exposure of 0.5 seconds for 
measuring fluorescence intensity using Metafluor software. 
Values for fluorescence intensity were compared between the 
groups treated and not treated with botulinum neurotoxin. The 
Student’s t-test was used for statistical analysis, and P , 0.05 
was considered statistically significant.
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Calcium imaging
Established cultures of human dorsal root ganglion neu-
rons were washed in phenol red free 4-(2-hydroxyethyl) 
 piperazine-1-ethanesulfonic acid, N-(2-hydroxyethyl) 
piperazine-N′-(2-ethanesulfonic acid) (HEPES)-buffered 
Hanks-balanced salt solution, containing 0.1% bovine serum 
albumin, and loaded with 2 µM Fura2 AM (acetoxymethyl 
ester) at 37°C for 40 minutes in the dark, with further incubation 
in HEPES-buffered Hanks-balanced salt solution containing 
0.5% bovine serum albumin for 20 minutes in the dark to allow 
for de-esterification of the cytosolic Fura2 AM. Experiments 
were conducted at 37°C in a humidified environment, as pre-
viously described.24 Live recordings of intracellular changes 
in bound and unbound Ca2+ ratios (340/380) were obtained 
before, during, and after addition of 200 nM capsaicin for 
baseline intracellular Ca2+, as well as changes in response to 
added capsaicin, in 2 mL of HEPES-buffered Hanks-balanced 
salt solution. A test stimulus of 200 nM capsaicin was applied 
for 15–30 seconds to test for capsaicin sensitivity, followed by 
washout and a change of medium for 30 minutes, after which 
a second stimulus of capsaicin 1 µM was applied. The differ-
ence in ratio between baseline to peak response was measured 
to give the magnitude of the response. Expressing the second 
response as a percentage of the first response gave the control 
response in the absence of botulinum neurotoxin. The effects 
of botulinum neurotoxins A or E were determined by applying 
the required concentration before the second capsaicin stimulus. 
Mean (± standard error of the mean) values for percent inhibi-
tion in the presence of botulinum neurotoxin were compared 
with those of controls without botulinum neurotoxin.
Results and discussion
In this study, we describe localization of the botulinum 
neurotoxin receptor protein, SV2A, in a range of human tis-
sues, including human dorsal root ganglion sensory neurons, 
peripheral nerves, urinary bladder, the colon, and the skin.
Dorsal root ganglia
SV2A immunoreactivity was present in neurons of all sizes, 
although those with a smaller diameter were more intense 
( Figure 1A and B), suggesting that botulinum  neurotoxin 
treatment may preferentially target nociceptor f ibers. 
 Normal uninjured peripheral nerves showed positive SV2A-
 immunoreactive fibers within the nerve fascicles (Figure 1C). 
In nerves proximal to injury and painful neuromas, SV2A 
immunoreactivity appeared to be increased (Figure 1E and G), 
and nerve immunostaining was similar to that seen with the 
structural nerve marker (neurofilaments, Figure 1D, F, and H). 
Image analysis (percent area of immunostaining) of these sam-
ples showed that SV2A was significantly increased in injured 
nerves compared with control uninjured nerves (P = 0.002, 
proximal injured nerves; P = 0.0027, neuromas), and sig-
nificantly greater in proximal injured nerves compared with 
neuromas (P = 0.0038, Figure 2). There was no change in the 
percent area of neurofilaments in these specimens; when results 
were expressed as the ratio of SV2A to neurofilaments, there 
was also a significant increase proximal to injury (P = 0.0022) 
and in neuromas (P = 0.0001), indicating an overall increase 
in SV2A expression in injured nerve fibers. Analysis of the 
delay between injury and surgery (percent area) suggested a 
peak of immunoreactivity at 2–16 weeks after injury.
Urinary bladder
SV2A-immunoreactive nerve fibers were detected throughout 
the bladder, including in detrusor muscle, and were associated 
with blood vessels, particularly in the urothelium/ suburothelial 
Figure 1 SV2A in neuronal tissues. SV2A immunoreactivity in avulsion injured dorsal 
root ganglion (A and B). SV2A immunoreactivity in normal uninjured nerve (C), 
nerve proximal to injury (E), and in a neuroma (G); corresponding serial sections 
(D, F, and H) immunostained with the nerve structural marker, neurofilaments, 
arrows indicate neuronal fibers, magnification 40×.
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junction region (Figure 3A–C). Image analysis of detrusor 
muscle showed a significant increase in the idiopathic detru-
sor overactivity group (P = 0.002) and also in the painful 
bladder syndrome group (P = 0.0087, Figure 3D) compared 
with controls. Image analysis of neurofilaments also showed 
a statistically significant difference in the idiopathic detrusor 
overactivity group (P = 0.008) compared with the controls. 
Expressing the results as a ratio of SV2A to neurofilaments 
showed no significant difference between any of the groups, 
suggesting that the observed increase in SV2A may be due 
to increased nerve fibers which express SV2A.
To our knowledge, this is the first report of SV2A levels 
in these patient groups. Our results for the distribution of 
SV2A in the human bladder are in agreement with others 
where SV2A was shown to be present in parasympathetic, 
sympathetic, and sensory fibers.25 Further studies, including 
double-staining with selective sensory and autonomic markers, 
are required to elucidate the nerve fiber subpopulations which 
show changed levels of SV2A in idiopathic detrusor over-
activity and painful bladder syndrome. We have previously 
demonstrated a decrease of both TRPV1 and the purinergic 
receptor, P
2
X
3
 in the suburothelium of the urinary bladder 
after highly effective botulinum neurotoxin A intradetrusor 
injections in patients with detrusor overactivity, while struc-
tural markers showed no loss of nerve fibers.20 Intracellular 
proteolytic cleavage of the synaptosomal-associated protein, 
SNAP-25, that regulates acetylcholine exocytosis, leads to pro-
longed blockade of synaptic transmission while sparing nerve 
endings.26 The progressive decrease of TRPV1 and P
2
X
3
, over 
the weeks following the injection treatment implies complex 
or multiple mechanisms of action for botulinum neurotoxin A 
in the bladder, with a progressive contribution to decreased 
levels of these sensory receptors by amelioration of bladder 
hypertrophy, or by decreased expression, uptake, or axonal 
transport of neurotrophic factors that regulate these recep-
tors, eg, nerve growth factor and glial-derived neurotrophic 
factor. Protein kinase C activation increased TRPV1 receptor 
surface expression in primary rat dorsal root ganglion neurons, 
and botulinum neurotoxin A fully blocked 12-O-tetrade-
canoylphorbol-13-acetate (TPA)-induced TRPV1 surface 
expression,21 which could explain the acute effect on urinary 
urgency in patients. In primary dorsal root ganglion neurons, 
TRPV1 codistributes in vesicles with synaptotagmin and the 
vesicular protein synaptobrevin; activity-dependent delivery of 
channels to the neuronal surface may contribute to the buildup 
and maintenance of thermal inflammatory hyperalgesia in 
peripheral nociceptor terminals, which may be blocked by 
botulinum neurotoxin A.21 In accord, botulinum neurotoxin A 
has been shown to have an antinociceptive effect on bladder 
afferent pathways in patients with painful bladder syndrome or 
 interstitial cystitis, producing both symptomatic and functional 
(ie, urodynamic) improvements.15
Colon
Colon biopsies from controls and from patients with irritable 
bowel syndrome and inflammatory bowel disease with or 
without painful symptoms showed SV2A-immunoreactive 
nerve fibers within the mucosa and muscularis mucosae 
( Figure 4A–D). Image analysis of SV2A mucosal fibers 
showed an increase only in quiescent inflammatory bowel 
disease with pain group (P = 0.023, Figure 4E), compared 
with controls, but not in those with inflammatory bowel 
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Figure 3 SV2A in the urinary bladder. SV2A-immunoreactive nerves (arrowed) 
in urothelium/suburothelial junction (arrowheads) (A), within the detrusor (B) 
and associated with blood vessel (arrowheads) within the suburothelium (C), 
magnification 40×, and image analysis of SV2A-immunoreactive fibers in the detrusor. 
Mean ± standard error of the mean of the percent area is shown (D).
Notes: *P = 0.008; **P = 0.0022.
Abbreviations: IDO, idiopathic detrusor overactivity; PBS, painful bladdersyndrome.
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Figure 2 Image analysis (percent area) of SV2A immunoreactivity in injured nerve. 
Mean ± standard error of the mean of the percent area is shown.
Notes: *P = 0.0027; **P = 0.002.
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disease without pain (P = 0.77) or in irritable bowel syn-
drome (P = 0.13). There was no difference between the 
mucosal neurofilament fibers or when results were expressed 
as a ratio of SV2A to neurofilaments in any of the groups 
studied. To our knowledge, this is the first description of 
SV2A in the colon mucosa of patients with irritable bowel 
syndrome and inflammatory bowel disease. Our finding 
of increased mucosal SV2A in patients with inflammatory 
bowel disease and abdominal pain are of interest, given that 
we have reported increased TRPV1 in this patient group.19 
Considering the previously observed effects of botulinum 
neurotoxin A on TRPV1 expression in patients with detru-
sor overactivity, this raises interesting clinical therapeutic 
possibilities in inflammatory bowel disease. The regulation 
of SV2A expression, effect of inflammation, and efficacy of 
botulinum neurotoxin A in inflammatory bowel disease all 
deserve further investigation.
Skin
In human skin, SV2A-immunoreactive fibers were prominent 
around sweat glands, arrector pili, and vascular  structures. 
Only a few intraepithelial fibers were seen in prefixed 
 specimens (Figure 5A–D). In normal rat paw skin, SV2A 
strongly stained nerve fibers in the subepithelium, within 
the epithelium, and around sweat glands (Figure 5E–F), 
indicating the usefulness of this antibody for preclinical 
studies in rodent models. Furthermore, this provides a basis 
for the reduction of neurogenic inflammation in rats follow-
ing transdermal botulinum neurotoxin A treatment.27 The 
dense innervation of SV2A-positive nerve fibers around 
sweat glands may explain why botulinum neurotoxin A is 
successful in the treatment of hyperhidrosis.28,29
Morphological effects of botulinum 
neurotoxin in dorsal root ganglia
Under differential interference contrast optics, normal 
untreated human dorsal root ganglion neurons showed 
few cytoplasmic vesicles and densely branched neurites 
 (Figure 6A). Neurons treated with botulinum neurotoxin E 
1 nM for one hour showed dense accumulation of cytoplasmic 
vesicles, and loss of neurites after 24 hours. Human dorsal 
root ganglion neurons treated with botulinum neurotoxin E 
0.1 nM for 48 hours also showed accumulation of cytoplasmic 
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Figure 4 SV2A in the human bowel. SV2A-immunoreactive fibers (arrowed) in 
control human colonic biopsies (A), irritable bowel syndrome (B), inflammatory 
bowel disease without pain (C) and inflammatory bowel disease with 
pain (D), arrowheads indicate villi, magnification 40× and image analysis of SV2A-
immunoreactive fibers in control IBS and quiescent IBD with (+P) and without pain 
(−P). Mean ± standard error of the mean of the percent area is shown (E). 
Note: *P = 0.023.
Figure 5 SV2A in human skin. SV2A-immunoreactive fibers (arrowed) in sweat 
glands (arrowheads) (A), around blood vessels (arrowheads) (B), arrector pili (C), 
and rare intraepithelial fiber, epithelial basal layer indicated by arrowhead (D) 
in human skin from a patient with small fiber neuropathy. Rat paw skin showing 
intraepithelial SV2A-immunoreactive fibers, epithelial basal layer indicated 
by arrowhead (E) and dense immunoreactive fibers around sweat glands 
(arrowheads) (F), magnification 40×.
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vesicles and loss of neurites up to 3 days later (Figure 6B). 
These effects were observed with comparable doses of both 
botulinum neurotoxins A and E. These changes are expected to 
be greater and more rapid in cultured neurons where the whole 
cell is exposed to the toxin, compared with the in vivo situa-
tion where only the nerve terminals may be initially exposed. 
The morphological effects of botulinum neurotoxin A and E 
treatment, ie, neurite loss and vesicle accumulation in the 
sensory neurons of the dorsal root ganglia observed in this 
study, are likely to result from disruption of the process of 
fusion of intracellular vesicles containing the proteins neces-
sary for the structural and functional integrity of the axon, in 
a manner similar to that observed in motor neurons, whereby 
cleavage of SNARE proteins within the presynaptic terminal 
by botulinum neurotoxin leads to prevention of the formation 
of the productive docking complex necessary for transmitter 
release, and consequent loss of function.24 A similar action of 
a recombinant chimera of botulinum neurotoxins A and E has 
been described in sensory neurons of the trigeminal ganglion 
affecting calcitonin gene-related peptide release.13
TRPV1 immunofluorescence in dorsal 
root ganglia
The effect of treatment with botulinum neurotoxins 
A and E on TRPV1 localization in cultured human dor-
sal root  ganglion neurons was determined by treating the 
neurons with botulinum neurotoxin A 0.1 nM and 1 nM and 
botulinum neurotoxin E at 1 nM, for one hour, before fixing 
with paraformaldehyde. Neurons not treated with botulinum 
neurotoxin showed cytoplasmic Gap43 immunostaining 
(green, Figure 6C), surrounded by membrane-bound red 
TRPV1 immunofluorescence. This pattern and intensity of 
staining were greatly diminished in botulinum neurotoxin-
treated neurons (Figure 6D). Quantification of TRPV1 
immunostained images showed approximately 60% reduction 
in signal intensity compared with untreated controls, at the 
concentrations used here, indicating the potency of the toxin 
in exerting its effects at low concentrations applied acutely for 
one hour. The average fluorescence intensity value (arbitrary 
units) for untreated controls was 39.3 ± 2.7 (n = 23 neurons), 
reduced to 14.17 ± 2.27 (n = 8 neurons, P , 0.0001) after 
botulinum neurotoxin A 0.1 nM treatment, 17.15 ± 3.8 
(n = 5  neurons, P , 0.0001) after botulinum neurotoxin A 
1 nM, and 16.8 ± 1.76 (n = 27 neurons, P , 0.0001) after 
botulinum neurotoxin E 1 nM treatment for one hour.
Calcium imaging
With single-cell studies using calcium imaging, we observed 
diminished calcium influx in response to the TRPV1 
ligand, capsaicin, following application of botulinum 
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Figure 6 In vitro effects of botulinum neurotoxin A and E treatment in human dorsal root ganglion neurons. Differential interference contrast image of a normal untreated 
neuron showing few intracellular organelles and densely branched neurites (A). Similar image of a neuron treated with botulinum neurotoxin E for 48 hours, showing 
dense accumulation of cytoplasmic vesicles and loss of neurites (B). Immunofluorescent image of an untreated neuron with membrane-bound intense TRPV1 localization 
(red) surrounding cytoplasmic Gap43 (green) appearing yellow in merged areas (C). Similar image showing diminished fluorescence intensity after one hour of botulinum 
neurotoxin A treatment (D). Sample trace of baseline ratio of bound and unbound Ca2+ and increase in ratio after capsaicin application (arrow, E). Trace showing diminished 
response to capsaicin (arrow) following pretreatment with 0.65 nM botulinum neurotoxin A (F). Graph showing dose-related percent inhibition of capsaicin responses 
following acute botulinum neurotoxin A treatment (G). Bar = 45 µm in B, applies to A, C, and D.
Note: ***P = 0.0036 for 0.65 nM botulinum neurotoxin A and P = 0.005 for 1 nM botulinum neurotoxin A. 
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neurotoxins A or E (Figure 6). Control neurons not treated 
with botulinum  neurotoxin showed, on average, 16.6% ± 5% 
inhibition (n = 6 neurons) caused by the known desensitization 
due to repeat capsaicin stimulation. The first stimulus was used 
to identify capsaicin-sensitive neurons and the second stimu-
lus was used to test the effect of botulinum neurotoxin after 
washout and change of medium, as described by our group 
 previously.24 Ten minutes of incubation with 0.00325 nM botu-
linum neurotoxin A resulted in 23.4% ± 6.7% inhibition (n = 11 
neurons, P = 0.27); 0.65 nM botulinum neurotoxin A resulted 
in 29.98% ± 2.3% inhibition (n = 6 neurons, P = 0.0036); 
and 1 nM botulinum neurotoxin A resulted in 45.1% ± 6% 
inhibition (n = 5 neurons, P = 0.005). Botulinum neurotoxin 
E-treated neurons showed 58.6% ± 8.4% inhibition (n = 4 
neurons, P = 0.008) after one hour of treatment with 0.1 nM 
botulinum neurotoxin E, and 97.8% ± 1.5% inhibition (n = 6 
neurons, P , 0.01) after 48 hours of treatment with 0.1 nM 
botulinum neurotoxin E. Botulinum neurotoxin E 1 nM treat-
ment for 10 minutes resulted in 25.04% ± 5.1% inhibition of 
capsaicin responses (n = 6 neurons, P = 0.19).
The TRPV1 receptor is actively transported in vesicles 
associated with the proteins synaptotagmin IX and snapin, and 
inserted in the plasma membrane by protein kinase C-regulated 
exocytosis, via a botulinum neurotoxin A-sensitive mecha-
nism.26 In agreement with this phenomenon, our results show 
the accumulation of vesicles within the cytoplasm of botuli-
num neurotoxin A-treated and botulinum neurotoxin E-treated 
neurons, correlating with diminished TRPV1 signal intensity 
and capsaicin responses. Botulinum neurotoxin effects on 
sensory neurons may thus be mediated by decreasing levels 
of sensory receptors, and blockade of their translocation to 
the plasma membrane. Further work using larger cohorts of 
different patient groups, together with further characteriza-
tion of SV2A immunoreactivity, are required to confirm the 
current findings. In addition, localization and identification 
of SNARE proteins in cultured dorsal root ganglia neurons, 
with and without botulinum neurotoxin treatment, would sup-
port our findings, and will form the focus of future research. 
The functional effects observed in this study, along with the 
distribution and levels of the receptor SV2A in normal and 
diseased human tissues, offer the potential of targeting a range 
of clinical conditions.
Conclusion
Differential levels of SV2A protein and changes in clinical 
disorders may provide potential and preferential targets for 
botulinum neurotoxin therapy, including painful  neuromas, 
urinary bladder disorders, and inflammatory bowel disease.30,31 
Novel designed agents based on neurotoxins and directed to 
molecular mechanisms underlying clinical disorders thus 
hold great promise for addressing unmet clinical needs. 
Selective targeted effects may advance treatment, eg, on 
sensory mechanisms in urinary bladder disorders, which 
may provide efficacy without motor dysfunction, and thereby 
avoid the need for bladder catheterization. Botulinum neuro-
toxin A and E treatment in cultured human sensory neurons 
produced morphological, molecular, and functional effects, 
supporting their use in clinical pain and hypersensitivity 
disorders, and the strategy of designing novel neurotoxins 
to target subsets of sensory nerve fibers.
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